Schrum Private Wealth Management LLC Sells 198 Shares of Johnson & Johnson $JNJ

Schrum Private Wealth Management LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,225 shares of the company’s stock after selling 198 shares during the quarter. Schrum Private Wealth Management LLC’s holdings in Johnson & Johnson were worth $798,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new stake in Johnson & Johnson during the first quarter valued at about $218,000. GAMMA Investing LLC lifted its holdings in Johnson & Johnson by 48.0% during the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock valued at $7,215,000 after purchasing an additional 14,118 shares during the last quarter. Davis Investment Partners LLC lifted its holdings in Johnson & Johnson by 7.9% during the first quarter. Davis Investment Partners LLC now owns 4,429 shares of the company’s stock valued at $682,000 after purchasing an additional 326 shares during the last quarter. Finally, Yarger Wealth Strategies LLC lifted its holdings in Johnson & Johnson by 6.2% during the first quarter. Yarger Wealth Strategies LLC now owns 1,560 shares of the company’s stock valued at $259,000 after purchasing an additional 91 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $190.66 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10. The firm’s fifty day moving average price is $178.48 and its 200-day moving average price is $163.76. The stock has a market cap of $459.16 billion, a P/E ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $24.02 billion for the quarter. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup upped their price objective on shares of Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Barclays increased their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Weiss Ratings raised shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $192.94.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.